Nuance Investments LLC Acquires Shares of 96,615 Becton, Dickinson and Company $BDX

Nuance Investments LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 96,615 shares of the medical instruments supplier’s stock, valued at approximately $14,621,000. Becton, Dickinson and Company comprises approximately 2.5% of Nuance Investments LLC’s holdings, making the stock its 12th largest holding.

Several other hedge funds have also added to or reduced their stakes in the stock. Auto Owners Insurance Co grew its position in shares of Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after acquiring an additional 40,528,680 shares during the period. Vanguard Group Inc. raised its holdings in shares of Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after purchasing an additional 4,223,149 shares during the period. BlackRock Inc. purchased a new position in Becton, Dickinson and Company in the second quarter valued at approximately $3,721,533,000. State Street Corp lifted its stake in Becton, Dickinson and Company by 0.8% in the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock valued at $2,714,871,000 after purchasing an additional 116,737 shares during the last quarter. Finally, First Eagle Investment Management LLC grew its holdings in Becton, Dickinson and Company by 16.5% during the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after purchasing an additional 1,651,592 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $182.39 on Tuesday. The business’s fifty day moving average is $158.48 and its 200 day moving average is $161.26. The firm has a market cap of $50.26 billion, a price-to-earnings ratio of 54.94, a PEG ratio of 12.93 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the company earned $3.68 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.3%. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Insiders Place Their Bets

In other news, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 11,779 shares of company stock valued at $1,974,669 in the last quarter. Corporate insiders own 0.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on BDX shares. UBS Group assumed coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 target price on the stock. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Bank of America dropped their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Barclays increased their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Finally, Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus target price of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.